QGEN - QIAGEN N.V.
| Previous Close | 38.12 |
| Open | 37.85 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 3200 |
| Day's Range | 37.80 - 38.20 |
| 52 Week Range | 30.20 - 39.45 |
| Volume | 549,441 |
| Avg. Volume | 843,067 |
| Market Cap | 8.659B |
| Beta | 1.04 |
| PE Ratio (TTM) | 115.58 |
| EPS (TTM) | 0.33 |
| Earnings Date | Oct 29, 2018 - Nov 2, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 39.41 |
- Zacks•2 days ago
QIAGEN (QGEN) Partners DiaSorin to Extend QuantFERON Offers
Per QIAGEN (QGEN), the latest LIAISON QuantiFERON-TB Plus Test is likely to tackle the growing transformation of global latent TB testing market into the modern blood-based QuantiFERON technology.
- Zacks•3 days ago
QIAGEN Collaborates With NeuMoDx, Expands NGS Portfolio
QIAGEN (QGEN) forges ahead with deals to strengthen the NGS Platform.
- Business Wire•3 days ago
QIAGEN and DiaSorin Launch Automated Testing for Latent TB infection with QuantiFERON-TB Gold Plus Technology on Widely Used LIAISON Platforms
CE-marked workflow enables efficient, high-throughput screening for tuberculosis control efforts in Europe and other markets; introduction in United States expected in 2019 and Chi
- Business Wire•3 days ago
QIAGEN and NeuMoDx Announce Strategic Partnership to Offer Next-Generation Systems for Fully Integrated Molecular Diagnostic Testing
QIAGEN to launch two Sample to Insight systems in Europe and other markets, NeuMoDx to commercialize in the U.S. / Initial assay menu for infectious diseases and LDTs
Markit•5 days agoSee what the IHS Markit Score report has to say about Qiagen NV.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last one-month, outflows of investor capital in ETFs holding QGEN totaled $100 million.
Market Realist•6 days agoWhy Is Pacific Biosciences Stock Up ~6.2% Today?
Today, Pacific Biosciences of California (PACB) is trading at $5.16 per share, up ~6.17% from yesterday’s close of $4.86. On September 12, Pacific Biosciences stock closed at $4.86, a 6.46% increase from its September 11 closing price of $4.57. Its September 12 stock price represented an ~141.0% rise from its 52-week low of $2.02 on April 2. Its stock price hit its 52-week high of $5.58 on October 3, 2017.
- Business Wire•7 days ago
QIAGEN to Join Germany’s MDAX Index in Addition to TecDAX
Frankfurt Prime Standard: QIA) announced today that its global shares will be included in Germany’s MDAX index as of September 24, 2018, in addition to the current listing in the country’s TecDAX index. The addition to the MDAX – which will now track the next 60 largest companies on the German stock market after the 30 largest stocks in the DAX index – comes as part of a reorganization of index rules adopted by Deutsche Boerse, operator of the Frankfurt Stock Exchange.
- Zacks•8 days ago
Here's Why You Should Retain QIAGEN (QGEN) in Your Portfolio
A tough competitive landscape and strong reliance on relationships with collaborative partners is a major deterrent to QIAGEN (QGEN). The company's increased focus on the NGS portfolio is a positive.
Markit•16 days agoSee what the IHS Markit Score report has to say about Qiagen NV.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last one-month, outflows of investor capital in ETFs holding QGEN totaled $128 million.
Markit•21 days agoSee what the IHS Markit Score report has to say about Qiagen NV.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
- Motley Fool•2 months ago
QIAGEN Gets Efficient While It Waits for the Next Growth Driver
Earnings grow faster than revenue as the diagnostic test company keeps costs in check.
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of QGEN earnings conference call or presentation 1-Aug-18 1:00pm GMT
Q2 2018 Qiagen NV Earnings Call
- Zacks•2 months ago
QIAGEN (QGEN) Beats Earnings and Revenue Estimates in Q2
QIAGEN's (QGEN) year-over-year revenue growth in Q2 is encouraging. Expansion in operating margin buoys optimism.
- ACCESSWIRE•2 months ago
QIAGEN NV to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / August 1, 2018 / QIAGEN NV (NYSE: QGEN ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 1, 2018 at 9:00:00 AM Eastern Time. To listen ...
- Business Wire•2 months ago
QIAGEN Creates Collaboration with Japan’s Largest Clinical Laboratory Testing Company, SRL, to Accelerate Launch of Companion Diagnostics
Day-one lab readiness speeds commercialization and reimbursement in personalized medicine
- Business Wire•2 months ago
QIAGEN’s careHPV™ Test Wins WHO Prequalification Status for Cervical Cancer Screening
Frankfurt Prime Standard: QIA) today announced that its careHPV™ Test, one of the only molecular diagnostics for high-risk human papillomavirus (HPV) designed to screen women in low-resource settings, has been added to the World Health Organization (WHO) list of prequalified in vitro diagnostics (IVDs). HPV is the primary cause of cervical cancer, so screening women for the presence of the virus is a critical aspect for prevention and early treatment of the deadly cancer.
- Zacks•2 months ago
Qiagen (QGEN) Tops Q2 Earnings and Revenue Estimates
Qiagen (QGEN) delivered earnings and revenue surprises of 3.13% and 0.08%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•2 months ago
Qiagen: 2Q Earnings Snapshot
On a per-share basis, the Venlo, Netherlands-based company said it had net income of 16 cents. Earnings, adjusted for non-recurring costs, came to 33 cents per share. The results exceeded Wall Street expectations. ...
- Business Wire•2 months ago
QIAGEN Reports Results for Second Quarter and First Half of 2018
QIAGEN reports results for second quarter and first half of 2018
- Business Wire•2 months ago
QIAGEN’s QuantiFERON-TB® Gold Plus Wins UN Migration Agency’s Tender
International Organization for Migration selects most advanced test for latent TB infection
- Business Wire•2 months ago
QIAGEN and Hamilton Launch New Collaboration to Improve Pre-Analytical Sample Processing for QuantiFERON-TB Gold Plus
Collaboration aims to accelerate adoption and ease of use in processing single-tube sample collection version of the market-leading modern blood test for latent TB detection
- Business Wire•2 months ago
QIAGEN N.V. to Report Second Quarter and First Half of 2018 Results
QIAGEN N.V. plans as previously announced to release its report on results for the second quarter 2018 on Tuesday, July 31 shortly after 22:00 Central European Time / 16:00 Eastern Daylight Time .
- Zacks•2 months ago
QIAGEN Test-Menu Expansion on Track, Low HPV Sales a Woe
QIAGEN's (QGEN) HPV sales in the United States remain tepid. Weak APAC sales are due to bleak applied testing business.
Markit•3 months agoSee what the IHS Markit Score report has to say about Qiagen NV.
Qiagen NV NYSE:QGEN
